Neuromyelitis Optica Spectrum Disorder

Disease State Hub

From the Journal

Photoclinic

Longitudinally Extensive Transverse Myelitis: A Rare Neuromyelitis Optica Spectrum Disorder

11/10/2022

A 57-year-old woman with a history of hypertension and polysubstance abuse presented with 2 weeks of progressive bilateral lower-extremity weakness.

11/10/2022

Research Summaries

Research summary

Early Serologic Diagnosis of AQP4+ NMOSD Based on Clinical Factors

08/22/2024

In a multicenter, retrospective study, researchers evaluated time from NMOSD onset to serological diagnosis and factors associated with predicting shorter time to diagnosis.

08/22/2024

Research summary

Research summary

Anxiety, Depression Prevalent in Patients Diagnosed With NMOSD

07/23/2024

A team of researchers sought to determine the prevalence of depression and anxiety in patients with NMOSD before their diagnosis of the disease.

07/23/2024

Research Summary

Meta-Analysis Highlights Clinical Differences Between Patients With NMOSD, MS

06/11/2024

Anthony Calabro, MA

A systematic review and meta-analysis examined the clinical differences between adult patients with neuromyelitis optica spectrum disorders and those with multiple sclerosis.

06/11/2024

RESEARCH SUMMARY

Study Points to Renal Dysfunction as a Potential Risk Factor for Relapse, Biomarker in Patients With NMOSD

05/20/2024

Anthony Calabro, MA

Researchers set out to determine whether renal function could be used as both a predictor of relapse risk for patients with their first onset of aquaporin-4 (AQP4)-immunoglobulin G (IgG)-seropositive...

05/20/2024

FDA

FDA

FDA Approves Treatment for Neuromyelitis Optica Spectrum Disorder

08/17/2020

The US Food and Drug Administration has approved a new treatment for neuromyelitis optica spectrum disorder among adults with the AQP4 antibody.

08/17/2020

August 2024

Current Issue

August 2024